Latent Tuberculosis in HIV positive, diagnosed by the M. Tuberculosis Specific Interferon-γ test by Brock, Inger et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Respiratory Research
Open Access Review
Latent Tuberculosis in HIV positive, diagnosed by the M. 
Tuberculosis Specific Interferon-γ test
Inger Brock2, Morten Ruhwald1, Bettina Lundgren2, Henrik Westh2, 
Lars R Mathiesen1 and Pernille Ravn*1
Address: 1Department for Infectious Diseases, University Hospital, Hvidovre 2650, Denmark and 2Department for Clinical Microbiology, 
University Hospital, Hvidovre 2650, Denmark
Email: Inger Brock - ibrock@dadlnet.dk; Morten Ruhwald - mruhwald@adslhome.dk; Bettina Lundgren - Bettina.Lundgren@hh.hosp.dk; 
Henrik Westh - Henrik.Westh@hh.hosp.dk; Lars R Mathiesen - larsmathiesen@dadlnet.dk; Pernille Ravn* - pravn@dadlnet.dk
* Corresponding author    
Abstract
Background: Although tuberculosis (TB) is a minor problem in Denmark, severe and complicated
cases occur in HIV positive. Since the new M. tuberculosis specific test for latent TB, the
QuantiFERON-TB In-Tube test (QFT-IT) became available the patients in our clinic have been
screened for the presence of latent TB using the QFT-IT test. We here report the results from the
first patients screened.
Methods: On a routine basis the QFT-IT test was performed and the results from 590 HIV
positive individuals consecutively tested are presented here. CD4 cell count and TB risk-factors
were recorded from patient files.
Main findings: 27/590(4.6%) of the individuals were QFT-IT test positive, indicating the presence
of latent TB infection. Among QFT-IT positive patients, 78% had risk factors such as long-term
residency in a TB high endemic area (OR:5.7), known TB exposure (OR:4.9) or previous TB disease
(OR:4.9). The prevalence of latent TB in these groups were 13%, 16% and 19% respectively. There
was a strong correlation between low CD4 T-cell count and a low mitogen response (P <
0.001;Spearman) and more patients with low CD4 cell count had indeterminate results.
Conclusion: We found an overall prevalence of latent TB infection of 4.6% among the HIV positive
individuals and a much higher prevalence of latent infection among those with a history of exposure
(16%) and long term residency in a high endemic country (13%). The QFT-IT test may indeed be a
useful test for HIV positive individuals, but in severely immunocompromised, the test may be
impaired by T-cell anergy.
Introduction
Tuberculosis (TB) is the most prevalent disease in human
immunodeficiency virus (HIV) positive and the majority
of the people at risk of HIV and TB are living in Sub Sahara
Africa [1]. The risk of developing active TB in HIV positive
individuals is increased many fold even when antiretrovi-
ral chemotherapy is given [2,3] and the incidence of TB is
increasing in regions where HIV is prevalent [1]. To pre-
vent further spread of TB, intensified efforts are needed
such as active case finding, and reducing the risk of reacti-
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vating TB in persons with latent tuberculosis infection
(LTBI), through prophylactic and antiretroviral treatment.
Diagnosis of early sputum negative tuberculosis and LTBI
has been hampered by low performance of the tools cur-
rently available. The Tuberculin Skin Test (TST) based on
Purified Protein Derivative (PPD) has been the most
important tool for the detection of LTBI for almost a cen-
tury. The main drawback of the TST is the lack of specifi-
city due to cross reactivity with proteins present in other
mycobacteria such as the Bacille Calmette Guèrin (BCG)
vaccine strain, M. avium complex organisms, and other
non tuberculous mycobacteria [4-7]. In addition, the sen-
sitivity of the TST is reduced in HIV positive
patients[2,4,8].
Identification of 3 M. tuberculosis specific antigens, ESAT-
6, CFP-10, and TB 7.7, has led to the development of a
whole new generation of M. tuberculosis specific diagnostic
tests [6]. ESAT-6, CFP-10, and TB 7.7 are contained within
the regions of the mycobacterial genome which are absent
from M. bovis BCG, M. avium and most other non-tuber-
culosis mycobacteria [6,9-11]. The M. tuberculosis specific
tests are based on the stimulation of sensitized T-lym-
phocytes followed by measurement of interferon-γ (IFN-
γ) by either enzyme linked immunoassay (ELISA) or
enzyme linked immunospot assay. The latest improve-
ment within this technology is the QuantiFERON® TB-
Gold In-Tube test (Cellestis, Australia), in which whole
blood is drawn directly into vacutainer tubes precoated
with antigens ready for incubation (QFT-IT test).
The sensitivity of the M. tuberculosis specific IFN-γ tests for
the diagnosis of active TB has in most studies been >85%
[12-15] and specificity in low TB risk populations 97–
100% [1,5,7,12-17] with a low number of indeterminate
test results. There is high a correlation between a positive
antigen specific IFN-γ response and the degree of TB expo-
sure [18-21] indicating that the test detects recent and
latent infection. Cross reactivity has not been reported
neither in healthy BCG vaccinated individuals
[12,13,16,17,20,22] nor in patients infected with M.
avium[5,7]. The only other mycobacteria which have been
shown to induce T-cell recognition of ESAT-6 and CFP-10
are M. marinum and M. kansasii[23]. Only very limited
information is available on the performance of IFN-γ tests
in HIV positive and immunocompromised individuals.
The incidence of TB in Denmark is low <10/105 inhabit-
ants/year [24] and the prevalence of HIV infection is 70/
105 inhabitants[25]. Every year 10–12 HIV positive indi-
viduals are diagnosed with active TB[24], corresponding
to a strikingly high incidence of TB in HIV positive of
>300/105 individuals/year. This high incidence suggests a
need for greater awareness and improved TB control
measures among HIV positive. When the M. tuberculosis
specific IFN-γ tests became commercially available in
Denmark in 2004, we decided to screen our patients for
LTBI using the QFT-IT test. We here report the results of
the first 590 HIV positive individuals who were tested
with the QFT-IT test.
Materials and methods
Study population
We used the QFT-IT test to screen for LTBI among the HIV
positive patients attending the outpatient clinic at the
University Hospital Hvidovre, Denmark. The clinic mon-
itors 1300 HIV positive patients out of a total of approxi-
mately 3050 known HIV positive persons in
Denmark[25]. Patients were screened during their routine
quarterly check-up. This check-up comprises clinical eval-
uation, control of viral load, CD4-cell count, compliance
with treatment, and an evaluation of potential side effects.
Patients with a positive QFT-IT test were evaluated to rule
out active TB. By reviewing the patient files, clinical infor-
mation was recorded, such as age, sex, ethnicity, year of
HIV diagnosis, AIDS defining diagnosis, previous treat-
ment for active TB, and on tuberculosis risk factors such as
exposure to an index case with sputum positive TB, history
of long term residency in a high endemic country (defined
as a country with a TB incidence >25:105), intravenous
drug use (IVDU) and factors assumed to influence
immune status such as alcohol abuse or diabetes.
QuantiFERON®TB-Gold In-Tube test
The QFT-IT test was performed at the Department for
Clinical Microbiology according to the manufacturer's
instructions; Briefly, 1 mL of blood was drawn directly
into vacutainer tubes coated with saline (negative con-
trol), peptides of ESAT-6, CFP-10 and TB-7.7, or PHA
(mitogen control). Tubes were incubated for 20 hours at
37°C, and plasma was harvested and frozen until further
analysis. The amount of IFN-γ produced was determined
using ELISA. IFN-γ release in the saline control tube (Nil)
was subtracted from the TB antigen and PHA stimulated
tubes. Samples with ≥0.35 IU/mL IFN-γ following stimu-
lation with M. tuberculosis specific antigens were consid-
ered positive, while samples with <0.35 IU/mL were
considered negative. The QFT-IT test result was considered
indeterminate if production of IFN-γ after stimulation
with PHA was < 0.5 IU/mL; indeterminate results could be
due to technical errors or anergy. Calculations were per-
formed using software provided.
Statistical methods
Median values, 25th  and 75th  percentiles and mean ±
standard deviations are shown. Median values were com-
pared using Mann Whitney ranked sum test. Trend analy-
sis was performed using non-parametric test for trend
across ordered groups. Chi-square test and Mc Nemar testsRespiratory Research 2006, 7:56 http://respiratory-research.com/content/7/1/56
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were used to compare proportions. The correlation
between CD4-cell count and the level of response to PHA
was assessed using Spearman correlation test. Calcula-
tions were performed using SAS, Med Calc and the SISA
software http://home.clara.net/sisa/.
From the Danish Data Protection Agency, permission to
analyze on data from the patient files was obtained
(Jr.nr.2005-41-5520).
Results
The screening was initiated October 2004 and by January
2005, 607 patients had been tested. In 17 patients, QFT-
IT results were not available due to technical or logistic
errors (i.e. samples left for too long before incubation, the
patient failed to go to the laboratory for the test) and were
not included in the data analysis. Baseline information for
590 HIV patients are shown in Table 1. Based on data
from the Danish HIV cohort[25], we believe that the
patients included are representative for the entire Danish
HIV population.
Baseline IFN-γ responses
The distribution of IFN-γ released upon stimulation with
either PHA or ESAT-6, CFP-10 and TB-7.7 are shown in
Figure 1. During the first months, 33 patients had blood
drawn twice with an interval of 1–12 weeks. Very low var-
iation was seen between the two time points. The median
IFN-γ production were 19.47 IU/mL and 19.74 IU/mL
respectively after PHA stimulation and 0.01 IU/mL and
0.01 IU/mL after stimulation with antigen (data not
shown). Three individuals changed from an indetermi-
nate PHA response to a positive response or the opposite.
Patient 1. changed from 1.72 IU/ml to 0.25 IU/ml, patient
2. from 1.69 IU/ml to 0,16 IU/ml, and patient 3. from
0.07 IU/ml to 6,72. Only patient converted from a nega-
tive (0.22 IU/ml) to a positive QFT-IT response (0.42 IU/
mL) in the second test 3 month later. This patient had
been visiting relatives in a high incidence area between the
two tests. The remaining patients were QFT-IT test nega-
tive on both tests. For data analysis the first sample was
always used. Of the 590 patients screened, 20(3.4%)
patients were not able to mount an IFN-γ response above
the cut-off (>0.5 IU/mL) in response to PHA and their
QFT-IT test results were considered "indeterminate". Of
570 patients with determinate test results, 27 were QFT-IT
test positive and 543 were QFT-IT test negative (Figure 2).
Prevalence latent and incidence of active TB
The overall prevalence of LTBI, determined by a positive
QFT-IT test result, was 4.6% (27/590) and 4.7% (27/570)
when patients with an indeterminate response were
excluded. After excluding all patients with a history of pre-
vious TB or indeterminate QFT-IT test result, the preva-
lence was 4.1% (22/542). One patient was already on
chemotherapy when the QFT-IT test was done and all
patients with positive QFT-IT tests were screened for active
TB. Within A one year period from of the QFT-IT test was
performed 2 patients, both QFT-IT positive, were diag-
nosed with active TB. One of the patients had completed
9 months of treatment 1 year prior, but had a relapse of
pulmonary TB. The other patient had been intensively
investigated for active TB due to unspecific symptoms and
9 month after the QFT-IT was done active TB was and
finally diagnosed in an abdominal lymph gland. Despite
Table 1: Baseline data for all the HIV positive screened with the 
QFT in tube test.
All 590
Age, median years (25th–75th quartile) 43 (37–50)
Male sex, no (%) 434 (74)
Ethnicity, no (%)
Danish 440 (74)
Non-Danish European 26 (4)
North American 4 (1)
African 78 (13)
Asian 26 (5)
Middle Eastern 10 (2)
Latin American 7 (1)
Tuberculosis no. (%)
Previous TB diagnosis 31 (5)
Tuberculosis risk factors, no (%)
History of exposure, 60 (10)
Long term residence in a TB endemic country a 122 (21)
IVDU 69 (12)
≥1 risk factor 218(37)
HIV status
Age at HIV diagnosis, median years (25th–75th quartile) 34 (28–41)
Years with HIV diagnosis, median years (25th–75th 
quartile)
8.5 (4–14)
AIDS diagnosed, no (%) 118 (20)
HAART treatment, no (%) 448 (76)
CD4 cell count
CD4 cell count, mean (± s.d.) 523 (± 
278)
0–99 CD4 cells/µL, (%) 17 (3)
100–199 CD4 cells/µL, (%) 37 (6)
200–300 CD4 cells/µL, (%) 63 (11)
>300 CD4 cells/µL4 7 3  ( 8 0 )
HIV RNA, no (%)
<500 copies/mL 439 (74)
500 – 50,000 copies/mL 95 (16)
>50,000 copies/mL 56 (9)
Factors presumed to influence immune status
Diabetes, no. (%) 20 (3)
Alc. Abuse, no (%) 63 (11)
aIncidence of TB >25/100,000.Respiratory Research 2006, 7:56 http://respiratory-research.com/content/7/1/56
Page 4 of 9
(page number not for citation purposes)
the low number of TB cases, the incidence of active TB
within the year of the screening was extremely high
7.407:105(2/27).
Identification of risk factors
Risk factor correlation was determined using results from
the 570 individuals with a valid QFT-IT test result (PHA
response >0.5 IU/mL). Covariates including age, sex, year
of HIV diagnosis, AIDS diagnosis, CD4-count, HIV RNA,
prior TB diagnosis, factors presumed to influence immune
status (alcohol abuse or diabetes) and tuberculosis risk
factors (history of TB exposure, long term residency in a
high endemic country and IVDU) were analysed (Table
2). The patients with a positive QFT-IT test had signifi-
cantly more risk factors than the QFT-IT negative patients;
78% (21/27) of the QFT-IT positive patients had one or
more TB risk factors in contrast to 34% (184/543) of the
patients with negative QFT-IT test (OR 7.2, CI: 2.8–18.2,
p= 0.00003). Of those with an indeterminate test,
65%(13/20) had risk factors for TB. Despite the low
number of patients with a positive QFT-IT test result, we
identified groups of individuals with an increased risk of
LTBI: patients with a history of TB exposure (OR 4.9, CI:
2.0–11.8, p= 0.001154) and patients with long term resi-
dency in a high endemic country (OR: 5.7, CI: 2.6–12.5, p
= 0.00002). Among patients with a history of previously
treated TB, there was an increased risk of a positive QFT-
IT test(OR: 4.9, CI: 1.7–14.1, p= 0.007). In contrast, age,
IVDU, alcohol abuse or diabetes, CD4-cell count or viral
load were not associated with positive QFT-IT test results.
The calculated odds ratios translated into a prevalence of
LTBI among HIV positive patients with a long term resi-
dency in a high endemic country of 13% (15/123) among
patients with a history of exposure of 16% (8/51), and
among patients with previous TB of 19% (5/27).
Nine-teen percent (5/27) of the QFT-IT positive individu-
als were previously treated for TB. The median interval
between TB diagnosis and the present QFT-IT test was 1,5
years (25th–75th quartile 0.5–4.3 years) for the patients
with a positive QFT-IT test in contrast to 6.5 years (25th–
75th quartile 4.4–9.4 years) for patients with a negative
QFT-IT test (p = 0.019, data not shown).
Influence of low CD4 cell count on the outcome of the 
QFT-IT test
We analyzed the possible effect of a low CD4 count on the
test performance and found a strong correlation (p <
0.001 Spearman) between the CD4-cell count and the
level of PHA stimulated IFN-γ production (data not
shown). The level of IFN-γ produced in response to PHA
by each individual has been stratified according to the
level of CD-4 cell count and is shown in Fig. 3. The
median IFN-γ levels as well as the proportion of patients
with indeterminate results is shown in Table 3. The
median IFN-γ release in the group with a CD4-cell count
<100 cells/µL was significantly lower than any of the three
other groups (Mann-Whitney ranked sum test: p <
0.0001) and there was a trend for increasing INF-γ release
for increasing CD4 group (non-parametric test for trend
across ordered groups (p < 0.0001). In addition, 24% (4/
17) of the patients with a CD4-cell count <100 cells/µL
had an indeterminate test result due to low INF-γ produc-
tion following PHA stimulation compared to only
IFN-γ release after stimulation of whole blood with either TB antigen (left) or Phytohaematglutinin (PHA)(mitogen) (right) Figure 1
IFN-γ release after stimulation of whole blood with either TB antigen (left) or Phytohaematglutinin (PHA)(mitogen) (right). All 
results are stratified into intervals according to the level of IFN-γ released after stimulation and the number of individuals with 
IFN-γ release within each interval are shown.
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2.8%(16/573) of the patients with a CD4 cell count >100
cells/µL (p < 0.0005).
Discussion
We found that the overall prevalence of LTBI (defined by
a positive QFT-IT test) of 4.6% among HIV positive in
Denmark was relatively low, but the prevalence of LTBI
was much higher among those with a history of residence
in a TB high endemic country (13%) or with known TB
exposure (16%). In low endemic countries very low prev-
alence of LTBI (0–3%) has been found independently of
BCG vaccination status [12,13,15-17,20]. In an interme-
diate endemic burden country, the prevalence of LTBI in
the general population was low 4%, increasing to 21% in
contacts of sputum positive TB patients[18]. In TB high
endemic regions, the prevalence of LTBI in the population
was 30%[19] increasing to 60–70% in household con-
tacts of TB patients[16,19] and to 40% in a group of
Indian health care workers[26]. Together, the QFT-IT test
appears to be very efficient in specific identification of
individuals at risk of LTBI. We did not find an association
between IVDU or alcohol abuse and being QFT-IT test
positive. This was unexpected since the impression is that
there is an increased risk of TB among patients with IVDU
and alcoholics in Denmark due to increased risk of expo-
sure[24,27].
Patients with a history of previously treated TB had a high
rate of positive QFT-IT test results(19%). The rate was
highest in patients with recent TB compared to patients
with TB many years ago suggesting that the QFT-IT test
response may diminish over time. There is an ongoing
Study Flow Diagram for 607 HIV positive patients screened with the QFT- IT test Figure 2
Study Flow Diagram for 607 HIV positive patients screened with the QFT- IT test. TB risk factors implies: prior TB diagnosis, 
history of TB exposure, history of long-term residency in a TB high endemic country (>25 cases per 100.000/year).
607 HIV+ve
patients tested
17 excluded due to technical or
logistic problems
590patients with valid
Quantiferon test
27 Quantiferon
positive
543 Quantiferon
negative
20 Quantiferon
indeterminate
211 TB
risk factor
6 no TB
risk
factors
184 1 TB
risk factor
131 TB
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7 no TB
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factorsRespiratory Research 2006, 7:56 http://respiratory-research.com/content/7/1/56
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debate whether it is possible to monitor the effect of
chemotherapy treatment using INF-γ based tests[28,29],
but the present study and previous reports[13,30], indi-
cate M. tuberculosis-specific responses can be retained for
many years after treatment. Whether this reflects differ-
ences in long term memory immunity or insufficient
treatment leading to persistent or latent infection is
unknown.
There is a relevant concern that the performance of the
QFT-IT test, in line with the TST, could be impaired by low
sensitivity in patients with advanced immunodeficiency.
The PHA control serves as a surrogate marker for anergy as
well as a quality control of the assay. In patients with a
CD4-cell count <100 cells/µL, we found a higher propor-
tion of indeterminate test results (24% vs 2.8%) due to
low PHA response and there was a significant correlation
between CD4-cell count and PHA induced IFN-γ release.
These findings support the hypothesis that the perform-
Table 2: Identification of risk factors for LTBI among HIV positive
QTF negative (n = 543) QTF positive (n = 27) OR, (95% CI) P values
Age, median years (25th–75th quartile) 43 (38–50) 42 (36–49) P = 0.05
Male sex, no (%) 405 (75) 17 (63)
Tuberculosis
Previous TB diagnosis no. (%) 22 (4) 5 (19) 4.9 (1.7–14.1) p= 0.0063
Tuberculosis risk factors, no. (%)
History of exposure 43 (8) 8 (30) 4.9 (2.0–11.8) p= 0.001154
Long term residence in a TB endemic country a 98 (17) 15 (56) 5.7 (2.6–12.5) p= 0.000021
IVDU b 59 (11) 5 (19) P= 0.110
≥1 risk factor 184 (34) 21 (78) 7.2 (2.9–18.2) p= 0.000003
HIV status
Age at HIV diagnosis, median years (25th–75th quartile) 34 (28–41) 34 (29–40) P = 0.11
Years with HIV diagnosis, median years (25th–75th quartile) 8.5 (4–14) 7 (4–11.0) P = 0.10
AIDS diagnosed, no (%) 107 (20) 6 (22) P = 0.18
HAART treatment, no (%) 416 (77) 19 (70) P = 0.13
CD4 cell count, mean (± s.d.) 523 (± 273) 600 (± 274) P = 0.17
0–99 CD4 cells/µL, (%) 13 (2) 0 (0)
100–199 CD4 cells/µL, (%) 35 (6) 1 (4)
200–300 CD4 cells/µL, (%) 55 (10) 2 (7)
>300 CD4 cells/µL,l 440 (81) 24 (89)
HIV RNA, no (%)
<500 copies per ml 412 (76) 18 (67) 0.10
500 – 50,000 copies per ml 79 (15) 8 (30)
>50,000 copies per ml 52 (10) 1 (4)
Factors presumed to influence immune status
Diabetes, no. (%) 18 (3) 2 (7) 0.18
Alc. Abuse, no (%) 59 (11) 3 (11) 0.24
aIncidence >25/100,000.
bIntravenous drug user
Differences between media n values were analysed using Mann-Withney test, and differences between proportions using Chi Square test
Table 3: Association between CD4 cell count and IFN-γ release in response to PHA.
CD4 cell counts1) No of patients Number and percentage of PHA non-
responders
IFN-γ release (Median and 25–75 
percentile)
<100 17 4 (24%)* 1,53 (0,34-19,49)#
100–199 37 1 (3%) 11.58 (3,88-30,11)
200–299 63 5 (8%) 16,78 (9,40-25,20)
>300 473 10 (2%) 20,35 (13,20–31,00)
1) cells/µl
* p < 0.0005, difference in the proportion of PHA-non-responders between patients with a CD4 cell count higher or lower than 100 cells/µL (Chi-
Square test).
# p = 0.0001 difference in the median IFN-γ release between patients with a CD4 cell count < 100 compared to groups of patients with a CD4 cell 
count ≥ 100 cells/µL (Mann-Withney U test) and there was a trend for increasing INF-γ release for increasing CD4 group (non-parametric test for 
trend across ordered groups (p < 0.0001).Respiratory Research 2006, 7:56 http://respiratory-research.com/content/7/1/56
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ance of the IFN-γ based tests is impaired in patients with
advanced immunosuppression. In vivo and in vitro anergy
in HIV positive individuals is well recognized [2-
4,8,31,32] and the reduced antigen response correlates
proportionally with CD4-cell count and is reversible dur-
ing antiretroviral treatment[3,32]. Fisk and colleagues
found that a CD4-cell count <100 cells/µL, was the critical
level associated with skin test anergy[32]. Limited data are
available on the performance of the IFN-γ test in HIV pos-
itive individuals. Converse and colleagues found, using
the 1st generation QuantiFERON® test based on tuberculin
PPD, a reduced rate of responders and a lower mean IFN-
γ response in HIV positive individuals with a low CD4-cell
count (<200 cells/µL)[8]. Other studies [15,33] have used
the ELISPOT test based on ESAT-6 and CFP-10 and found
that the number of responders as well as the mean IFN-γ
response was reduced in HIV positive individuals. How-
ever neither CD4-cell count or AIDS diagnosis, were avail-
able in either study. A small study including 29 HIV
positive patients surprisingly concluded that there was no
impact of a low CD4-cell count on the performance of the
IFN-γ response in an ELISPOT assay[34]. However, based
on our findings and the numerous reports demonstrating
reduced T-cell function in HIV patients it is most likely
that the M. tuberculosis specific IFN-γ responses are
impaired in patients with advanced immunosuppression
in both ELISPOT and whole blood assays.
There is not yet consensus on how to determine the criti-
cal level of immunosuppression which may impair the
performance of the tests. Reducing the cut off level is a
possibility, but may result in the loss of specificity. An
alternative is to define a cut-off level of CD4-cells at which
the sensitivity of the IFN-γ is impaired. Until further infor-
mation has been obtained, we argue that PHA is used as
the currently best described control and emphasize the
need for careful interpretation of an indeterminate or neg-
ative test result in HIV positive with low a CD4 cell count
(i.e. <100–200 cells/µL). Despite these considerations it is
worth noticing that 76% of the patients with a low CD4-
cell count did respond to stimulation with PHA.
TST was not performed in parallel with the QFT-IT screen-
ing, which is of course a constrain to the overall evalua-
tion of the results. TST however, is not routinely
performed in our patients because most of the HIV posi-
tive patients were born before 1975 and thus BCG vacci-
nated and a poor specificity of the TST is expected. Despite
this, a TST would have contributed to understanding of
the differences between the TST and QFT-IT in HIV posi-
tive.
Perspectives
The M. tuberculosis specific QFT-IT test offers methodolog-
ical and logistic advantages over the TST. It requires only
one patient visit and plasma can be frozen for later analy-
sis. It does not induce a boosting phenomenon that is
seen with the TST due to repeated injections of mycobate-
rial antigens. Once established in the laboratory, repro-
ducibility is high as shown herein. The number of steps
resulting in direct contact with potentially contagious
blood from HIV positive individuals is minimal with the
In-Tube test system, thus reducing the occupational haz-
ards of performing TB testing. By introducing the M. tuber-
culosis specific tests, we may be able to improve TB control
by specific identification of those HIV positive individuals
with LTBI. A positive QFT-IT test is strongly suggestive of
LTBI whereas an indeterminate test result or a negative
QFT-IT test result in the severely immunocompromised
hosts should always be interpreted with caution
Conclusion
Using the QFT-IT test, we found an overall prevalence of
LTBI of 4.6% in HIV positive individuals and a much
higher prevalence of LTBI among patients with known
exposure(16%) and residency in a high endemic coun-
try(13%). Two cases of active TB was found among 27
QFT-IT positive patients resulting in an extremely high
incidence of TB (7.4%). The QFT-IT test may be a useful
IFN-γ release (IU/mL) after stimulation of whole blood with  PHA (mitogen) Figure 3
IFN-γ release (IU/mL) after stimulation of whole blood with 
PHA (mitogen). Results are stratified into intervals according 
to the CD4-cell count for each individual. The median IFN-γ 
values within each CD4-cell count interval are indicated with 
horizontal lines. Cut off for PHA response of 0.5 IU/ml is 
shown by a dotted line.
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new test for detecting LTBI in immunocompetent HIV
positive individuals and future studies should be designed
to determine the critical lower level of CD4-cells and to
determine the role of these tests in high endemic regions.
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